Sangamo Therapeutics Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Sangamo Therapeutics de 65.2% y 41.8% respectivamente, mientras que el BPA crecerá en un 60.9% al año.
Información clave
65.2%
Tasa de crecimiento de los beneficios
60.9%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 27.7% |
| Tasa de crecimiento de los ingresos | 41.8% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 13 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You
Oct 23
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
Oct 21There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump
Aug 03Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Jul 23Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Jun 19We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
May 29This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
May 14Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate
Mar 09Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet
Feb 02Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Dec 04Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?
Sep 11Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
Aug 15Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S
Aug 08Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be
May 30Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)
May 13Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Apr 11We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully
Dec 20Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
Sep 22Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Sep 18Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
Aug 31Sangamo Therapeutics: Cheap, But Justifiably So
Aug 09Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
May 08Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?
Apr 11Sangamo Therapeutics: Lost In Transition From Lab To Clinic
Feb 24Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 97 | -50 | 49 | 59 | 6 |
| 12/31/2025 | 74 | -49 | -28 | -18 | 7 |
| 12/31/2024 | 66 | -86 | -98 | -93 | 2 |
| 9/30/2024 | 52 | -135 | -117 | -114 | N/A |
| 6/30/2024 | 12 | -250 | -179 | -173 | N/A |
| 3/31/2024 | 19 | -328 | -218 | -207 | N/A |
| 12/31/2023 | 176 | -258 | -246 | -225 | N/A |
| 9/30/2023 | 201 | -250 | -257 | -231 | N/A |
| 6/30/2023 | 218 | -199 | -265 | -238 | N/A |
| 3/31/2023 | 241 | -127 | -258 | -231 | N/A |
| 12/31/2022 | 111 | -192 | -244 | -224 | N/A |
| 9/30/2022 | 112 | -178 | -235 | -219 | N/A |
| 6/30/2022 | 114 | -172 | -241 | -225 | N/A |
| 3/31/2022 | 113 | -176 | -242 | -224 | N/A |
| 12/31/2021 | 111 | -178 | -257 | -233 | N/A |
| 9/30/2021 | 109 | -181 | -209 | -185 | N/A |
| 6/30/2021 | 138 | -135 | -116 | -92 | N/A |
| 3/31/2021 | 131 | -124 | 101 | 120 | N/A |
| 12/31/2020 | 118 | -121 | 155 | 170 | N/A |
| 9/30/2020 | 147 | -76 | 136 | 153 | N/A |
| 6/30/2020 | 111 | -102 | 64 | 81 | N/A |
| 3/31/2020 | 107 | -96 | -137 | -118 | N/A |
| 12/31/2019 | 102 | -95 | -165 | -144 | N/A |
| 9/30/2019 | 74 | -118 | -206 | -164 | N/A |
| 6/30/2019 | 76 | -104 | -200 | -152 | N/A |
| 3/31/2019 | 80 | -90 | -37 | 10 | N/A |
| 12/31/2018 | 84 | -68 | -7 | 37 | N/A |
| 9/30/2018 | 71 | -63 | 44 | 60 | N/A |
| 6/30/2018 | 59 | -62 | N/A | 72 | N/A |
| 3/31/2018 | 46 | -58 | N/A | 6 | N/A |
| 12/31/2017 | 37 | -55 | N/A | 11 | N/A |
| 9/30/2017 | 32 | -51 | N/A | 16 | N/A |
| 6/30/2017 | 23 | -58 | N/A | 14 | N/A |
| 3/31/2017 | 19 | -72 | N/A | -59 | N/A |
| 12/31/2016 | 19 | -72 | N/A | -66 | N/A |
| 9/30/2016 | 20 | -76 | N/A | -63 | N/A |
| 6/30/2016 | 25 | -66 | N/A | -60 | N/A |
| 3/31/2016 | 30 | -52 | N/A | -52 | N/A |
| 12/31/2015 | 40 | -41 | N/A | -34 | N/A |
| 9/30/2015 | 45 | -31 | N/A | -27 | N/A |
| 6/30/2015 | 49 | -29 | N/A | -19 | N/A |
| 3/31/2015 | 51 | -24 | N/A | -19 | N/A |
| 12/31/2014 | 46 | -26 | N/A | -6 | N/A |
| 9/30/2014 | 38 | -30 | N/A | -5 | N/A |
| 6/30/2014 | 31 | -29 | N/A | -3 | N/A |
| 3/31/2014 | 28 | -27 | N/A | 0 | N/A |
| 12/31/2013 | 24 | -27 | N/A | -19 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que SGMO siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que SGMO siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que SGMO siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (41.8% al año) de SGMO crezcan más rápidamente que los del mercado US (9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (41.8% al año) de SGMO crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SGMO se prevé que sea elevada dentro de 3 años.